Mbx Biosciences Inc (MBX) is trading down at $50.46 (-6.43%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on MBX
One firm's current price target on Mbx Biosciences Inc: $90 — 78% above the current $50.5. Each is tracked to its date and scored the same way a member's call is.
- UBS $57.5 → $90 by Sep 2027 Sep 28, 2026 via Investing.com · UBS's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Mbx Biosciences Inc net income history (FY2023–FY2025)
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$35.3M | −$68.2M | −$98.1M |
| Net income | −$32.6M | −$61.9M | −$87.0M |
| EPS (diluted) | −$31.96 | −$5.82 | −$2.38 |
| Balance sheet | |||
| Cash and equivalents | $30.5M | $49.4M | $75.3M |
| Total assets | $84.2M | $268.5M | $385.1M |
| Total liabilities | $4.29M | $11.1M | $15.9M |
| Shareholders' equity | −$72.5M | $257.4M | $369.2M |
| Cash flow | |||
| Operating cash flow | −$32.0M | −$54.7M | −$79.9M |
| Capital expenditure | $129.0K | $874.0K | $1.93M |
| Free cash flow | −$32.1M | −$55.6M | −$81.9M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$19.6M | −$18.6M | −$26.5M | −$21.8M | −$23.9M | −$25.8M | −$27.3M | −$40.9M |
| Net income | −$18.1M | −$15.6M | −$23.9M | −$19.4M | −$21.6M | −$22.1M | −$23.5M | −$37.1M |
| EPS (diluted) | −$2.78 | $19.84 | −$0.71 | −$0.58 | −$0.63 | −$0.46 | −$0.50 | −$0.78 |
| Balance sheet | ||||||||
| Cash and equivalents | $132.9M | $49.4M | $29.9M | $39.8M | $223.1M | $75.3M | $45.2M | $54.1M |
| Total assets | $282.4M | $268.5M | $245.9M | $231.5M | $400.1M | $385.1M | $452.7M | $435.9M |
| Total liabilities | $11.0M | $11.1M | $10.5M | $12.3M | $12.5M | $15.9M | $14.9M | $26.4M |
| Shareholders' equity | $271.4M | $257.4M | $235.4M | $219.2M | $387.5M | $369.2M | $437.8M | $409.5M |
| Cash flow | ||||||||
| Operating cash flow | −$14.7M | −$16.0M | −$22.7M | −$17.4M | −$21.5M | −$18.3M | −$20.2M | −$22.6M |
| Capital expenditure | $57.0K | $92.0K | $30.0K | $707.0K | $399.0K | $793.0K | $437.0K | $901.0K |
| Free cash flow | −$14.7M | −$16.1M | −$22.7M | −$18.1M | −$21.9M | −$19.1M | −$20.6M | −$23.5M |
From Mbx Biosciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Mbx Biosciences Inc
- Headquarters
- Carmel, Indiana From SEC filings, Oct 2026
Recent News (2)
-
MBX Biosciences to Participate in Upcoming November Investor Conferences CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commer…
-
UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data
UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International